Palatin TechnologiesPTN
About: Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.
Employees: 30
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
2,150% more call options, than puts
Call options by funds: $45K | Put options by funds: $2K
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
9% more funds holding
Funds holding: 33 [Q2] → 36 (+3) [Q3]
9.81% less ownership
Funds ownership: 18.06% [Q2] → 8.25% (-9.81%) [Q3]
75% less capital invested
Capital invested by funds: $5.68M [Q2] → $1.43M (-$4.25M) [Q3]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Joseph Pantginis 22% 1-year accuracy 91 / 410 met price target | 600%upside $7 | Buy Maintained | 13 Feb 2025 |
Financial journalist opinion
Based on 6 articles about PTN published over the past 30 days









